Status:
COMPLETED
A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
Lead Sponsor:
Genentech, Inc.
Conditions:
Turner Syndrome
Eligibility:
FEMALE
Up to 17 years
Brief Summary
This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States a...
Eligibility Criteria
Inclusion
- Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin
- Are willing to keep follow-up appointments throughout study participation
- Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9
Exclusion
- Have Noonan syndrome
- Subjects treated within the last 6 months with a non-Genentech GH preparation
- Have closed epiphyses prior to NCGS enrollment
- Have active neoplasia
Key Trial Info
Start Date :
May 1 1997
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1696 Patients enrolled
Trial Details
Trial ID
NCT00097552
Start Date
May 1 1997
End Date
July 1 2010
Last Update
November 14 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.